Sino Biopharmaceutical (HKG:1177) completed the enrollment of the first patient in a phase I clinical trial of LM-350, developed by unit LaNova Medicines, in Australia, a Thursday Hong Kong bourse filing said.
The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of the drug in patients with advanced solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.